Pharmacoeconomics Research Unit

Publications & Presentations

Papers published (selected)

Selected Reports

Poster Presentations (selected)

  • Lee L, Khor S, Hoch J, Luo J, Bremner K, Krahn M, Crump M, Hodgson D.  “Impact of Rituximab on Outcomes of Very Elderly Patients with Diffuse Large B-Cell Lymphoma”, presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2011.
  • Khor S, Djalalova D, Hoch J.  “How attractive does a set of guidelines have to be to warrant correct adoption and utilization”, presented at the Annual Meeting of the Society for Medical Decision Making, Toronto, Ontario, October 2010.
  • Djalalov S, Yong J, Saposnik G, Musa Z, Mendelson M, Hoch J.  “Is Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment Cost-Effective in Canada?“, presented at the Canadian Agency for Drugs and Technologies in Health (CADTH) Invitational Symposium, Halifax, Nova Scotia, April 2010.
  • Hoch J, Earle C, Gavura S, Hart J, Kamel-Reid S, Khor S, Lalonde B, Ross J, Sawka C.  “Cost-effectiveness analysis of personalized medicine: Case studies from the real world”, presented at Cancer Care Ontario Research Day, Toronto, Ontario, April 2010.
  • Lee L, Khor S, Crump M, Hoch J, Bremner K, Krahn M, Hodgson D.  “Challenges in the Identification of Accurate Pathological Diagnoses and Treatment for B-cell Lymphoma:  A Comparison of Ontario Databases”, presented at Cancer Care Ontario Research Day, Toronto, Ontario, April 2010.
  • Yong JHE, Djalalov S, Hoch J. “Economic Evaluation Studies Submitted to Inform Cancer Drug Funding Decisions: A Closer Look at the Quality and Limitations” presented at the Annual Meeting of the Society for Medical Decision Making, Boston, Philadelphia, Pennsylvania, October 2008.

Invited and Peer-reviewed Presentations (selected)

  • Yong J. “Value for money in cancer – IMRT as a Case Study“, presented at the 4th International Cancer Control Congress, National Cancer Centre, Republic of Korea, 2011.
  • Khor S, Krahn M, Hodgson D, Bremner K, Luo J, Hoch J. “Real-world Cost-effectiveness Analysis of Cancer Drugs: Comparative effectiveness research using retrospective Canadian registry data before and after drug approval“, presented at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting, Baltimore, May 2011.
  • Khor S, Krahn M, Hodgson D, Bremner K, Luo J, Hoch J.  “Real world cost-effectiveness of cancer drugs“, presented at the Canadian Agency for Drugs and Technologies in Health (CADTH) Invitational Symposium, Vancouver, British Columbia, April 2011.
  • Khor S, Djalalova D, Hoch J.  “The Paradox of the Laupacis Parallax“, presented at the Canadian Agency for Drugs and Technologies in Health (CADTH) Invitational Symposium, Halifax, Nova Scotia, April 2010.
  • Hoch J, Peacock S, Van Der Hoek K, Musa Z.  “Addressing Research and Development Needs with a National Centre for Health Economics, Services, Policy and Ethics“, presented at the Canadian Agency for Drugs and Technologies in Health (CADTH) Invitational Symposium, Halifax, Nova Scotia, April 2010.
  • Hoch J. “Decision-Making and Economic Evaluation of Genetic Testing”,  presented at the invitational symposium: Genetic Testing: the Future is Here, Mount Sinai Hospital, Toronto, Ontario, March 2010.
  • Djalalov S. “Economic Evaluation of Genetic Testing in Combination with Preventive Donepezil Treatment for Amnestic Mild Cognitive Impairment (AMCI) Patients”,  presented at the invitational symposium: Genetic Testing: the Future is Here, Mount Sinai Hospital, Toronto, Ontario, March 2010.
  • Khor S.  “Personalized Medicine in the Real World” and “Making Sense of Using Thresholds”,  presented at the invitational symposium: Genetic Testing: the Future is Here, Mount Sinai Hospital, Toronto, Ontario, March 2010.
  • Musa Z. “Research in Other Jurisdictions and the Canadian Centre for Applied Research in Cancer Control (ARCC)”,  presented at the invitational symposium: Genetic Testing: the Future is Here, Mount Sinai Hospital, Toronto, Ontario, March 2010.
  • Hoch J. “Frankenstein, Dracula and net benefit regression: What you need to know,” a keynote presentation at the Canadian Association for Population Therapeutics Conference, Montreal, Quebec, April 2009.
  • Hoch J. “Getting better value for money with pharmacoeconomics: How to stop wasting your money” presented at the 7th Annual Market Access Summit, Toronto, Ontario, December 2008.
  • Hoch J, “Preliminary findings from the Chair of the Joint Oncology Drug Review’s subcommittee on Pharmacoeconomics,” presented to the Joint Oncology Drug Review, Toronto, Ontario, June 2008.
  • Hoch J. “How the pharmacoeconomics unit at Cancer Care Ontario has and could help” presented to the Assistant Deputy Minister and Executive Officer of the Ontario Public Drug Programs (OPDP), Toronto, Ontario, May 2008.
  • Hoch J. “Deliberations on deliberative processes: Deliberately using economic evidence?” presented as part of the workshop “Evidence, Context and Optimal Decisions: Getting there through deliberative processes” at the Canadian Agency for Drugs and Technologies in Health (CADTH) Invitational Symposium, Ottawa, Ontario, April 2008.
  • Hoch J. “Considerations for reimbursement approval of new anti-cancer drugs: International experiences” presented at the 2nd Taiwan Pharmacoeconomics Seminar: Value of Anti-Cancer Therapy, Taipei, Taiwan, April 2008.
  • Hoch J. “Is the invisible hand giving the invisible finger to KT?” presented at Clinical Epidemiology Rounds, Toronto General Hospital, Toronto, Ontario, December 2007.
  • Hoch J. “Using economics to make decisions that benefit people with cancer: The development and application of methods to optimize the creation, evaluation and use of economic evaluations of cancer treatments” presented to the Committee to Evaluate Drugs (CED), Cancer Care Ontario (CCO) Subcommittee, Toronto, Ontario, October 2007.
  • Hoch J. “ICER Thresholds: What’s the Right Number?” presented at the Pharmaco-economics workshop for the Drug Quality and Therapeutics Committee (DQTC), Toronto, Ontario, November 2006.